1. Home /
  2. Biotechnology

Biotechnology

BeyondSpring CEO Reveals Novel Tumor Therapy

BeyondSpring CEO Reveals Novel Tumor Therapy

The company is working on regulatory approvals in the U.S. and China.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn shares plummeted Monday after Germany's Fresenius Medical ditched its planned $5 billion takeover amid allegations of data misconduct at the Lake Forest, Ill.-based generic drugmaker.

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue

What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle. Here's what that could mean for regulation of legal cannabis in the U.S.

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discuss Friday jitters, trading the missile strike, and oncology stocks to watch.

In Biopharma M&A, 'Where There's Real Innovation There's Someone Willing to Pay'

In Biopharma M&A, 'Where There's Real Innovation There's Someone Willing to Pay'

Deals in biopharma slowed in 2017 for the third consecutive year. According to Intec Pharma CEO Jeffrey Meckler, just because volume is down doesn't mean it's out.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.